The next-generation sequencing (NGS) market is expected to be APAC’s fastest-growing in-vitro diagnostics segment between now and 2025. More healthcare providers are recognising the significant advantages of this technology for prenatal testing and cancer diagnosis, which is driving widespread NGS adoption in the region and creating opportunities for IVD company growth.

Clearstate offers market data, forecasts, and trend predictions to give you the insight to adjust your business strategy to meet the growing opportunities in MDx.

Transcatheter aortic valve replacements (TAVR) is set to be Japan’s fastest-growing procedural areas in cardiac surgery. Opportunities are growing particularly as the number of TAVR candidates rises in an aging population, and with an expanding indication towards younger, lower-risk patients.

Transcatheter aortic valve replacements (TAVR) is set to be one of the fastest-growing procedural areas in cardiac surgery for Asia. Opportunities are growing particularly in east Asia as the number of TAVR candidates rises in an aging population, and with an expanding indication towards younger, lower-risk patients.

Access to Transcatheter aortic valve replacements (TAVR) procedures in China will grow rapidly as maturing infrastructure and greater device options due to technical developments combine with the availability of domestically developed devices.

Understand the future of cardiac surgery in Asia with Clearstate’s latest report which examines Asia’s TAVR market landscape and the strategy implications that could enable improvements in TAVR access for the region.

Understand & track the medical consumables’ market size, share & growth data for more than 200 product segments. Contact Economist Intelligence’s Clearstate & learn more.

2022 healthcare megatrends shaping IVD

How will broad healthcare trends influence in-vitro diagnostic (IVD) testing? What role do technologies play in shaping the future of clinical testing?

This infographic looks at three trends in healthcare that will shape the surgical device sector in 2022: automation, robotics and artificial intelligence (AI), connected care, and telehealth.

Emergent covid-19 screening technologies coupled with declining testing demand are likely to erode the molecular-based covid-19 test market in Asia-Pacific (APAC) over the next five years

Molecular diagnostics (MDX) instrument sales in Asia-Pacific (APAC) are expected to normalise in the next few years.

Molecular diagnostics (MDx) testing capacities and capabilities in Asia-Pacific (APAC) countries have rapidly improved to meet the exponential surge in demand for covid-19 testing.